Taking a Lesson From Microbial Diarrheagenesis in the Management of Chronic Constipation

Gastroenterology

Volumn 138, Issue 3, 2010, Pages 813-817

  Bharucha, Adil E ^a   Waldman, Scott A ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DISULFIDE; GASTROINTESTINAL AGENT; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; LINACLOTIDE; NATRIURETIC FACTOR; NITRIC OXIDE; PANCREATIN; UNCLASSIFIED DRUG;

BACTERIAL SURVIVAL; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; EDITORIAL; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77249162216     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.01.022     Document Type: Editorial

References (27)

1. Lembo A.J., Kurtz C.R., MacDougall J.E., et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138 (2010) 886-895
2. Kosek M., Bern C., and Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bulletin of the World Health Organization 81 (2003) 197-204
3. Forte L.R. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 81 (1999) 25-39
4. Hamra F.K., Eber S.L., Chin D.T., et al. Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc Natl Acad Sci U S A 94 (1997) 2705-2710
5. Carpick B.W., and Gariepy J. The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin. Infect Immun 61 (1993) 4710-4715
6. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52 (2000) 375-414
7. Forte Jr. L.R. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 104 (2004) 137-162
8. Alderete J.F., and Robertson D.C. Repression of heat-stable enterotoxin synthesis in enterotoxigenic Escherichia coli. Infect Immun 17 (1977) 629-633
9. Guttman J.A., and Finlay B.B. Subcellular alterations that lead to diarrhea during bacterial pathogenesis. Trends Microbiol 16 (2008) 535-542
10. Harris L.A., and Crowell M.D. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 9 (2007) 403-410
11. Kessler M, Busby R, Wakefield J, et al. Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation. 15th North American ISSX Meeting. San Diego, 2008.
12. Andresen V., Camilleri M., Busciglio I.A., et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133 (2007) 761-768
13. Talley N.J. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia. Am J Gastroenterol 104 (2009) 1339-1341
14. Chiarioni G., Whitehead W.E., Pezza V., et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 130 (2006) 657-664
15. Ravi K., Bharucha A.E., Camilleri M., et al. Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology (2009 Aug 4) [Epub ahead of press]
16. Debongnie J.C., and Phillips S.F. Capacity of the human colon to absorb fluid. Gastroenterology 74 (1978) 698-703
17. Cohen M.B., Guarino A., Shukla R., et al. Age-related differences in receptors for Escherichia coli heat-stable enterotoxin in the small and large intestine of children. Gastroenterology 94 (1988) 367-373
18. Ironwood and Forest announce positive linaclotide results from two pivotal Phase 3 trials in patients with chronic constipation. Ironwood Pharmaceuticals Press Release. http://www.ironwoodpharma.com Accessed December 15, 2009
19. Camilleri M., Beyens G., Kerstens R., et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 21 (2009) 1256-e117
20. Quigley E.M., Vandeplassche L., Kerstens R., et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29 (2009) 315-328
21. Tack J., van Outryve M., Beyens G., et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58 (2009) 357-365
22. Johanson J.F., Morton D., Geenen J., et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103 (2008) 170-177
23. Bijkerk C.J., de Wit N.J., Muris J.W.M., et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?. Randomised placebo controlled trial. BMJ 339 (2009) b3154
24. Dipalma J.A., Cleveland M.V., McGowan J., et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 102 (2007) 1436-1441
25. Kienzle-Horn S., Vix J.M., Schuijt C., et al. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 23 (2006) 1479-1488
26. Shailubhai K., Gerson W., Talluto C., et al. A randomized, double-blind, placebo-controlled, single-, ascending-, oral-dose safety, tolerability and pharmacokinetic study of SP-304 in healthy adult human male and female volunteers. Digestive Disease Week (2008) San Diego
27. Waldman S.A., and Terzic A. Therapeutic targeting: a crucible for individualized medicine. Clin Pharmacol Ther 83 (2008) 651-654